Other substances

Withanoside V

A withanolide glycoside.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

Withanoside V on PubChem

 

Structure image - Withanoside V

CC1=C(C(=O)O[C@H](C1)[C@@H](C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4([C@H](C[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)O)O)C)C)C

Supporting references

Link Tested on Impact factor Notes Publication date
Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants – Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) – a molecular docking study
3CLpro Small molecule In silico 		in silico 3.22

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Aug/27/2020

AI-suggested references

Link Publication date
Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor
Oct/07/2021
Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) - a molecular docking study.
Aug/27/2020
Export (.csv)